SPC 3
Latest Information Update: 04 Sep 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 12 Nov 1999 Columbia Laboratories has not exercised its option for a license to the rights to SCP 3
- 19 Oct 1998 Profile reviewed
- 16 Aug 1996 Phase-II clinical trials for HIV infections treatment in USA (Unknown route)